GlobeNewswire Inc | Dec 27, 2021 09:00PM EST

December 28, 2021

NEW YORK, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) on behalf of Corcept stockholders. Our investigation concerns whether Corcept has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that [o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorneys Office for the District of New Jersey (the NJ USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcepts relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym. Corcept further disclosed that [t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena.

On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

If you purchased or otherwise acquired Corcept shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Contact Information:

Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Alexandra B. Raymond, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com